AR040134A1 - Formulacion para la administracion parenteral de un bloqueante del canal del na - Google Patents
Formulacion para la administracion parenteral de un bloqueante del canal del naInfo
- Publication number
- AR040134A1 AR040134A1 ARP030101863A ARP030101863A AR040134A1 AR 040134 A1 AR040134 A1 AR 040134A1 AR P030101863 A ARP030101863 A AR P030101863A AR P030101863 A ARP030101863 A AR P030101863A AR 040134 A1 AR040134 A1 AR 040134A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- composition according
- acid
- yeta
- cyclodextrin
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- Vascular Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10223783A DE10223783A1 (de) | 2002-05-29 | 2002-05-29 | Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040134A1 true AR040134A1 (es) | 2005-03-16 |
Family
ID=29432393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101863A AR040134A1 (es) | 2002-05-29 | 2003-05-28 | Formulacion para la administracion parenteral de un bloqueante del canal del na |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1511517B1 (enExample) |
| JP (1) | JP2005527615A (enExample) |
| AR (1) | AR040134A1 (enExample) |
| AT (1) | ATE373492T1 (enExample) |
| AU (1) | AU2003237664A1 (enExample) |
| CA (1) | CA2487150A1 (enExample) |
| DE (2) | DE10223783A1 (enExample) |
| ES (1) | ES2294295T3 (enExample) |
| PE (1) | PE20040066A1 (enExample) |
| TW (1) | TW200400029A (enExample) |
| UY (1) | UY27823A1 (enExample) |
| WO (1) | WO2003099336A1 (enExample) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4239877C1 (de) * | 1992-11-27 | 1994-03-17 | Boehringer Ingelheim Int | Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung |
| DE4313408A1 (de) * | 1993-04-23 | 1994-10-27 | Boehringer Mannheim Gmbh | Cyclodextrin-Biocid-Komplex |
| FR2713934B1 (fr) * | 1993-12-22 | 1996-01-12 | Commissariat Energie Atomique | Utilisation de cyclodextrines aminées pour la solubilisation aqueuse de composés hydrophobes, en particulier de molécules pharmaceutiquement actives. |
| DE19740110A1 (de) * | 1997-09-12 | 1999-03-18 | Boehringer Ingelheim Pharma | Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US6565880B2 (en) * | 2000-07-24 | 2003-05-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea |
| DE10223784A1 (de) * | 2002-05-29 | 2003-12-11 | Boehringer Ingelheim Pharma | Neue Formulierung zur parenteralen Applikation von Crobenetine |
-
2002
- 2002-05-29 DE DE10223783A patent/DE10223783A1/de not_active Withdrawn
-
2003
- 2003-05-23 CA CA002487150A patent/CA2487150A1/en not_active Abandoned
- 2003-05-23 WO PCT/EP2003/005399 patent/WO2003099336A1/de not_active Ceased
- 2003-05-23 ES ES03735445T patent/ES2294295T3/es not_active Expired - Lifetime
- 2003-05-23 AU AU2003237664A patent/AU2003237664A1/en not_active Abandoned
- 2003-05-23 EP EP03735445A patent/EP1511517B1/de not_active Expired - Lifetime
- 2003-05-23 JP JP2004506859A patent/JP2005527615A/ja active Pending
- 2003-05-23 AT AT03735445T patent/ATE373492T1/de not_active IP Right Cessation
- 2003-05-23 DE DE50308227T patent/DE50308227D1/de not_active Expired - Fee Related
- 2003-05-27 UY UY27823A patent/UY27823A1/es not_active Application Discontinuation
- 2003-05-27 PE PE2003000511A patent/PE20040066A1/es not_active Application Discontinuation
- 2003-05-28 TW TW092114414A patent/TW200400029A/zh unknown
- 2003-05-28 AR ARP030101863A patent/AR040134A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UY27823A1 (es) | 2003-12-31 |
| AU2003237664A1 (en) | 2003-12-12 |
| DE50308227D1 (de) | 2007-10-31 |
| PE20040066A1 (es) | 2004-03-22 |
| EP1511517A1 (de) | 2005-03-09 |
| ES2294295T3 (es) | 2008-04-01 |
| JP2005527615A (ja) | 2005-09-15 |
| ATE373492T1 (de) | 2007-10-15 |
| CA2487150A1 (en) | 2003-12-04 |
| DE10223783A1 (de) | 2003-12-11 |
| TW200400029A (en) | 2004-01-01 |
| EP1511517B1 (de) | 2007-09-19 |
| WO2003099336A1 (de) | 2003-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR8569A (es) | Inhibidores de integrasa de vih | |
| AR061620A1 (es) | Suspensiones acuosas de tmc278 | |
| CL2011003266A1 (es) | Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras. | |
| UY37952A (es) | Formulaciones de un inhibidor de la quinasa trk macrocíclica | |
| AR050717A1 (es) | Composiciones farmaceuticas | |
| ECSP11010854A (es) | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol | |
| HRP20210945T1 (hr) | Formulacije protutijela anti-cd19 | |
| AR045016A1 (es) | Derivados de 5-carbamimidoi-2-metilsulfaniltiofen-3-sulfonil como inhibidores conjugados de la cascada de complemento y su uso en el tratamiento de enfermedades. | |
| CL2007001710A1 (es) | Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras. | |
| DOP2005000064A (es) | Nuevos compuestos | |
| CL2008002689A1 (es) | Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia. | |
| CL2009001077A1 (es) | Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo. | |
| AR066544A1 (es) | Metodos de utilizacion de antagonistas de la vasopresina con agentes para quimioterapia con antracina para reducir la cardiotoxicidad y/o aumentar la supervivencia. composicion farmaceutica. | |
| ECSP11011001A (es) | Composición farmacéutica sólida | |
| AR076263A1 (es) | Composiciones y metodos para tratar cancer. uso. | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| MX2023010545A (es) | Inhibidores de integrinas alfa v beta 6 y alfa v beta 1 y usos de los mismos. | |
| NI200700031A (es) | Formulaciones de ácido hidroxamico suberoilanilida y procedimientos para la producción de las mismas | |
| AR065034A1 (es) | Metodos para prevenir y tratar trastornos neurodegenerativos | |
| ES2150404T3 (es) | Composiciones farmaceuticas de tizoxanida y nitozoxanida. | |
| AR045423A1 (es) | Combinaciones de analiticos y antidepresivos | |
| AR074724A1 (es) | Sal de citrato 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo (19.3.1.1(2,6).1(8,12) heptacosa-1-(25),2(26),3,5,8,10,12 (27),16,21,23-decaeno | |
| CO2020001742A2 (es) | Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil | |
| ATE420089T1 (de) | Substituierte azachinazoline mit antiviraler wirkung | |
| AR074725A1 (es) | Sal de maleato de 11-(2-pirrolidin-1-il-etoxi)-14,19- dioxa-5,7,26-triaza-tetraciclo(19.3.1.1 (2,6).1 (8,12) heptacosa-1(25),2 (26),3,5,8,10,12 (27),16,21,23-decaeno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |